LBG’s Georgia Sloboda was recently recognized by The Corporate Magazine
Georgia Sloboda, Managing Director, CMC at LBG was recently recognized by The Corporate Magazine for her leadership expertise.
Georgia Sloboda, Managing Director, CMC at LBG was recently recognized by The Corporate Magazine for her leadership expertise.
Written by LBG’s Dan Vest, “Avoiding Conflicts of Interest,” was recently published in Contract Management magazine. The article focuses on new legislation regarding Organizational Conflicts of Interest (OCIs), which was …
Innovations that are shaping the future of bioscience, engineering, and digital technology take front and center at the Innovation Festival, presented by BioKansas, on August 3 – 5 in Kansas …
The contracting future with AI, FAR/DFARS regulatory updates, and the applicability of federal requirements on nonprofits, state, and local governments are a few trending topics that LBG’s Dan Vest looks …
Clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of laboratory medicine are just a few key topics of discussion at the 2023 AACC Annual Scientific …
Robert Huebner, Ph.D. was recently appointed to the Missouri Biotechnology Association (MOBIO) Board of Directors. The MOBIO Board of Directors assists and helps guide MOBIO leadership by promoting the enrichment …
LBG was recently awarded a grant by the Bill & Melinda Gates Foundation to develop an easy-to-use, web-based modeling tool for use in determining the cost of goods of pharmaceutical …
Written by LBG’s Lauren Schoukroun-Barnes, Ph.D., Dianne Cantara, Sarah DeDonder, Ph.D., and Dawn Speidel, “Pharmaceutical Manufacturing Quality Assurance Programs: Transitioning from Research and Development to the Clinic” was recently published in BioProcess International. The article …
Therapeutic frontiers, the business of biotech, regulatory and policy outlooks, and human capital are just a few of the trending topics of discussion at the BIO International Convention. LBG Partners …
The record number of gene, gene-modified cell therapies since last year and the recent approval of Gamida Cell’s Omisirge off-the-shelf allogeneic therapy raises an important question: How are other advanced …